Liar’s Poker is one of those books one of your friends strongly urges you to read. A short little book, the recommendation I got from Bill Howe, my Canadian Intel colleague in Europe, was that it was a hilarious read. And so it was. It reads like Animal House. Michael Lewis also recently wrote The Big Short, his analysis of the 2008 financial meltdown. Liar’s Poker has been described as a comedy, and The Big Short as a tragedy, which seems very apt to me if you have heard Michael discuss both books. Many may know Michael best for his recent success with Moneyball.


An insightful interview with Reid Hoffman, venture capitalist and founder of LinkedIn. But to my mind, Hoffman seems blase’ about Big Ideas and “deep tech” funding. I share the views of Startup Genome founder, Max Marmer, and bemoan the limited focus of VC’s on world-changing technologies, leaving it to billionaire angels. I also sense myopia about the ongoing intense debate over the distortion of the sharing economy by Uber, Airbnb, and others.


Pfizer’s announcement this week of its intricate $160 Billion merger/acquisition with Irish pharmaceutical company Allergan, revealed that Pfizer will be moving the new corporate headquarters to Dublin. Essentially, Pfizer, the much larger company, is providing a bridging loan to Allergan to purchase Pfizer so that it may move to Ireland. This enables Pfizer to avoid paying U.S. taxes, even after receiving massive support for R&D from U.S. government programs.


The sale and breakup of a flagship technology company is a reoccurring theme in Canadian business. But this time is different. If BlackBerry Ltd.goes, there is no ready replacement. That’s a telling switch from the situation Canada faced with the sale of Newbridge Networks in 2000 and the demise of Nortel Networks in 2009. More than a decade of declining business investment in research and development has left Canada without an obvious BlackBerry successor. Despite bright spots in Waterloo, Ont., and Ottawa, the country’s performance on most of the important benchmarks of innovation has been deteriorating for years.